Tuesday, January 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

BAA for Enhanced Platelet Regeneration Following Radiation Exposure

by Global Biodefense Staff
April 3, 2013

Nuclear and Radiological Medical CountermeasuresThe National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals to advance the development of candidate medical countermeasures (MCMs) to enhance platelet regeneration and increase survival following radiation exposure. 

The effort is managed under a Broad Agency Announcement (BAA) released this week entitled “Development of Medical Countermeasures to Enhance Platelet Regeneration and Survival Following Radiation Exposure from a Radiological/Nuclear Incident.”

NIAID anticipates that research and development studies supported by the BAA will advance candidate countermeasures toward eventual Food and Drug Administration (FDA) approval or licensure to treat radiation-induced thrombocytopenia and thereby improve survival. 

The government is looking to stockpile MCMs for civilian use that yield a significant survival benefit when administered at greater than 24 hours after radiation exposure and are easy to use (delivered by oral, subcutaneous, inhaled, transdermal, intramuscular, or intravenous methods). As such, candidates chosen for further development under this BAA must demonstrate efficacy when administered at least 24 hours after exposure. 

Radiation exposure type, dose level, and dose rates proposed for studies need to be relevant to a terrorist incident or accidental exposure, such as a nuclear power plant accident. Studies using fractionated radiation exposures, commonly used for clinical radiotherapy treatments would not be appropriate, unless information gained would be directly applicable to an unintentional exposure scenario.

The government estimates that 2-4 contracts will be awarded for a 3-year period of performance beginning June 2014. Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2013166. The response deadline is July 1, 2013.

Tags: BAARadiation

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC